This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cimino, G. Articles by Nervi, C. Search for Related Content PubMed PubMed Citation Articles by Cimino, G. Articles by Nervi, C.

Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia

Departments of ¹ Cellular Biotechnology and Hematology and ² Histology and Medical Embryology, University of Rome "La Sapienza"; ³ Department of Biopathology, University of Rome "Tor Vergata"; ⁴ San Raffaele Bio-medical Park Foundation Rome, Italy and ⁵ European Institute of Oncology, Milan, Italy

Requests for reprints: Clara Nervi, Department of Histology and Medical Embryology, University of Rome "La Sapienza" and San Raffaele Bio-medical Park Foundation, Via di Castel Romano 100, 00128 Rome, Italy. Phone: 39-6-80319049/52; Fax: 39-6-80319054; E-mail: clara.nervi{at}uniroma1.it.

Epigenetic alterations of chromatin due to aberrant histone deacetylase (HDAC) activity and transcriptional silencing of all-trans retinoic acid (ATRA) pathway are events linked to the pathogenesis of acute myeloid leukemia (AML) that can be targeted by specific treatments. A pilot study was carried out in eight refractory or high-risk AML patients not eligible for intensive therapy to assess the biological and therapeutic activities of the HDAC inhibitor valproic acid (VPA) used to remodel chromatin, followed by the addition of ATRA, to activate gene transcription and differentiation in leukemic cells. Hyperacetylation of histones H3 and H4 was detectable at therapeutic VPA serum levels (50 µg/mL) in blood mononuclear cells from seven of eight patients. This correlated with myelomonocytic differentiation of leukemic cells as revealed by morphologic, cytochemical, immunophenotypic, and gene expression analyses. Differentiation of the leukemic clone was proven by fluorescence in situ hybridization analysis showing the cytogenetic lesion +8 or 7q– in differentiating cells. Hematologic improvement, according to established criteria for myelodysplastic syndromes, was observed in two cases. Stable disease and disease progression were observed in five and one cases, respectively. In conclusion, VPA-ATRA treatment is well tolerated and induces phenotypic changes of AML blasts through chromatin remodeling. Further studies are needed to evaluate whether VPA-ATRA treatment by reprogramming differentiation of the leukemic clone might improve the response to chemotherapy in leukemia patients. (Cancer Res 2006; 66(17): 8903-11)

This article has been cited by other articles:

				D. Nowak, D. Stewart, and H. P. Koeffler Differentiation therapy of leukemia: 3 decades of development Blood, April 16, 2009; 113(16): 3655 - 3665. [Abstract] [Full Text] [PDF]

				B. Hackanson, H. Becker, T. Berg, M. Binder, C. Dierks, J. Duque-Afonso, M. D. Lairmore, H. S. Schafer, M. Schnitzler, R. Zeiser, et al. XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from Molecular Pathogenesis to Targeted Therapy in Leukemia and Solid Tumors Cancer Res., July 15, 2008; 68(14): 5512 - 5518. [Full Text] [PDF]

				J. K. Countryman, L. Gradoville, and G. Miller Histone Hyperacetylation Occurs on Promoters of Lytic Cycle Regulatory Genes in Epstein-Barr Virus-Infected Cell Lines Which Are Refractory to Disruption of Latency by Histone Deacetylase Inhibitors J. Virol., May 15, 2008; 82(10): 4706 - 4719. [Abstract] [Full Text] [PDF]

				S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Blood, February 1, 2008; 111(3): 1428 - 1436. [Abstract] [Full Text] [PDF]

				A. O. Soriano, H. Yang, S. Faderl, Z. Estrov, F. Giles, F. Ravandi, J. Cortes, W. G. Wierda, S. Ouzounian, A. Quezada, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood, October 1, 2007; 110(7): 2302 - 2308. [Abstract] [Full Text] [PDF]

				T. Siitonen, T. Timonen, E. Juvonen, V. Terava, A. Kutila, T. Honkanen, M. Mikkola, H. Hallman, M. Kauppila, P. Nylanden, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes Haematologica, August 1, 2007; 92(8): 1119 - 1122. [Abstract] [Full Text] [PDF]

				F. Fazi, G. Zardo, V. Gelmetti, L. Travaglini, A. Ciolfi, L. Di Croce, A. Rosa, I. Bozzoni, F. Grignani, F. Lo-Coco, et al. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia Blood, May 15, 2007; 109(10): 4432 - 4440. [Abstract] [Full Text] [PDF]

				G. Bug, K. Schwarz, C. Schoch, M. Kampfmann, R. Henschler, D. Hoelzer, O. G. Ottmann, and M. Ruthardt Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia Haematologica, April 1, 2007; 92(4): 542 - 545. [Abstract] [Full Text] [PDF]